ClinicalTrials.gg
WithdrawnNCT07677865GLP1-AD-TTEUpdated Oct 16, 2026

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

An observational study in Alzheimer Disease, Diabetes Mellitus Type 2 and Obesity & Overweight, sponsored by West China Hospital. Withdrawn at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by West China Hospital · Observational

How we know · 6 judgments

Why this study was withdrawn
poor accrual and funding issues
Updated Oct 16, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
0
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 260 studies in Alzheimer Disease with a site in China — 150 open to participants now, 162 under way, 21 of them phase 3. Alzheimer Disease · China.

Enrollment
84th of 84
0 · median 566
Started
2007
with 2 others
Observational
84 of 260
56 open now
Registered
239th of 260
by date

Among the 260 studies in Alzheimer Disease with a site in China, this one is the 84th largest by enrollment of the 84 observational ones that give a count, is one of 3 that started in 2007, is one of 84 observational ones, and was the 239th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

150 of the 260 studies in Alzheimer Disease with a site in China are open now. Recruiting first, the newest first:

145 more — sign in →

All 150 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 260 studies in Alzheimer Disease with a site in China, or all of them as a file.
02

Study summary

Background: Seven large real-world cohort studies (N > 4 million) have consistently reported that glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a 19-54% lower incidence of Alzheimer's disease (AD). However, in November 2025, the phase 3 EVOKE and EVOKE+ trials of oral semaglutide in 3,808 patients with biomarker-confirmed early-stage AD failed to slow clinical progression. This paradox between real-world evidence (RWE) and randomised evidence has not been systematically examined. Moreover, prior RWE studies were conducted predominantly in North American and European populations, leaving a critical generalisability gap for East Asian populations, who face the world's largest AD burden.

Objective: To resolve the RWE-RCT paradox by testing whether the GLP-1RA effect on AD differs between cognitively unimpaired adults (primary prevention paradigm) and patients with established cognitive impairment (treatment paradigm), and to assess whether the protective effect is consistent across European, African, and East Asian ancestries.

Study Design: This is a multi-centre, retrospective, observational cohort study using a target trial emulation framework. The investigator analysed patient-level electronic health records (EHR) from five cohorts across four continents: Optum® Clinformatics® (USA), Mass General Brigham Biobank (USA), CPRD Aurum (UK), the Swedish National Diabetes Register (Sweden), and the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System (HKHA CDARS), which covers approximately the entire Hong Kong population.

Study Population: A total of 2,138,917 adults aged ≥ 40 years with type 2 diabetes or obesity, with ≥ 2 years of continuous enrolment and no prior neurodegenerative disease diagnosis. GLP-1RA initiators (n = 612,418) were compared with DPP-4 inhibitor initiators (n = 1,526,499) using propensity-score overlap weighting, Fine-Gray competing-risk adjustment, negative-control outcomes, and instrumental-variable analysis to address confounding and surveillance bias.

03

Conditions studied

  • Alzheimer Disease
  • Diabetes Mellitus Type 2
  • Obesity & Overweight

Keywords

  • glucagon-like peptide-1 receptor agonist
  • Alzheimer disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults aged ≥ 40 years with type 2 diabetes (ICD-10 E11) or obesity (E66) from five EHR-linked cohorts across four continents: Optum Clinformatics (USA), Mass General Brigham Biobank (USA), CPRD Aurum (UK), Swedish National Diabetes Register (Sweden), and Hong Kong Hospital Authority CDARS (Hong Kong SAR)

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Age ≥ 40 years

      • Diagnosis of type 2 diabetes (ICD-10 E11) or obesity (E66)
      • ≥ 2 years of continuous enrolment in the cohort
      • Baseline \< 10.5%
      • No prior diagnosis of any neurodegenerative disease
      • No prior use of any GLP-1RA or DPP-4i

Exclusion criteria

Exclusion Criteria:

    • Prior diagnosis of Alzheimer's disease or other neurodegenerative diseases

      • Prior use of GLP-1 receptor agonists or DPP-4 inhibitors
      • Age \< 40 years
      • Baseline ≥ 10.5%
      • Less than 2 years of continuous enrolment
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • GLP-1 Receptor Agonist (GLP-1RA) Initiators

    Drug: GLP-1 Receptor Agonists

  • DPP-4 Inhibitor (DPP-4i) Initiators

    Drug: DPP-4 Inhibitors

Interventions

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Incidence of Alzheimer's Disease

    Measurement Tool: International Classification of Diseases, Tenth Revision (ICD-10) diagnostic code G30 (Alzheimer's disease), extracted from linked electronic health records (EHR) and hospitalization databases across all participating cohorts. Diagnostic validity was confirmed via chart review against biomarker-confirmed AD (amyloid PET, CSF Aβ42, or plasma p-tau217), with a positive predictive value (PPV) ranging from 68.9% to 71.3% in validation samples. Unit of Measure: Time to first incident diagnosis, expressed as Hazard Ratio (HR) with 95% confidence intervals, comparing GLP-1 receptor agonist initiators versus DPP-4 inhibitor initiators. Incidence rates are also reported as number of events per 1,000 person-years. Scale Information: Not applicable (this is a time-to-event diagnostic outcome, not a rating scale).

    Time frame: Up to 10 years (from index date of medication initiation to date of first AD diagnosis, death, or end of follow-up, whichever occurs first).

Secondary outcomes

  1. Incidence of All-Cause Dementia.

    Measurement Tool: ICD-10 codes for any dementia diagnosis, including Alzheimer's disease (G30), vascular dementia (F01), and unspecified dementia (F03), extracted from EHR and hospitalization records. Unit of Measure: Time to first diagnosis, expressed as Hazard Ratio (HR) with 95% CI. Scale Information: Not applicable (diagnostic outcome).

    Time frame: Up to 10 years

  2. Rate of Progression from Mild Cognitive Impairment (MCI) to Alzheimer's Disease

    Measurement Name: Rate of Progression from MCI to AD. Measurement Tool: ICD-10 code G31.84 (Mild cognitive impairment) at baseline, followed by subsequent ICD-10 code G30 (Alzheimer's disease) during follow-up, extracted from EHR. Unit of Measure: Time to progression, expressed as Hazard Ratio (HR) with 95% CI, specifically analyzed within the EVOKE-eligible patient subgroup (those with baseline cognitive impairment). Scale Information: Not applicable (diagnostic progression outcome).

    Time frame: Up to 10 years

  3. Rate of All-Cause Mortality.

    Measurement Tool: Death records linked from national or regional death registries (e.g., Hong Kong Death Registry, Swedish National Death Registry, UK Office for National Statistics). Unit of Measure: Time to death, expressed as Hazard Ratio (HR) with 95% CI, analyzed using Fine-Gray subdistribution hazard models to account for competing risks. Scale Information: Not applicable (mortality outcome).

    Time frame: Up to 10 years.

Other outcomes

  1. Incidence of Four Negative Control Outcomes.

    Measurement Tool: ICD-10 codes for Amyotrophic Lateral Sclerosis (ALS, G12.21), Ingrown Toenail (L60.0), Acute Appendicitis (K35), and Accidental Injury (V01-X59), extracted from EHR. Unit of Measure: Hazard Ratio (HR) with 95% CI for each outcome, comparing GLP-1RA vs DPP-4i initiators. These outcomes are expected to yield null associations (HR \~ 1.0) to validate that unmeasured confounding is minimal. Scale Information: Not applicable (diagnostic outcome).

    Time frame: Up to 10 years.

07

Study locations

1 site
  • West China Hospital of Sichuan University
    Chengdu, Sichuan, China
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2007 to primary completion in Dec 2024, 215 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 1, 2026
StartActual
Jan 1, 2007
Primary completionActual
Dec 31, 2024
CompletionActual
Jun 24, 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Withdrawn poor accrual and funding issues
changed Oct 16, 2026
Enrollment
213891→0
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Completed→Withdrawn
    Why stopped poor accrual and funding issues
    Enrollment 213891→0
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07677865
Responsible party
Zhigang Lan (Professor, West China Hospital) — Principal investigator
First posted
Jul 1, 2026
Start date
Jan 1, 2007
Primary completion
Dec 31, 2024
Completion
Jun 24, 2026
Last update
Oct 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion